Results 61 to 70 of about 287,802 (318)
Is there a gender effect in polycythemia vera? [PDF]
Annals of Hematology, 2020 AbstractIn recent times, there has been a growing interest in understanding the impact of gender on disease biology and clinical outcomes in Philadelphia-negative chronic myeloproliferative neoplasms. Among those, polycythemia vera (PV) is characterized by increased thrombotic risk, systemic symptoms, and overall reduced survival.
Palandri F. +3 more
openaire +5 more sources
Újdonságok, aktualitások a polycythaemia vera diagnosztikájában és kezelésében | Diagnosis and treatment of polycythaemia vera: state of the art [PDF]
, 2016 Absztrakt A polycythaemia vera a Philadelphia-negatív krónikus myeloid neoplasiák közé tartozó ritka neoplasia, amelyre az emelkedett vörösvérsejttömeg okozta hiperviszkozitás a jellemző.
Borbényi, Zita +2 more
core +1 more source
American journal of hematology/oncology, 2018 Disease Overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding,
A. Tefferi, T. Barbui
semanticscholar +1 more source
American Journal of Hematology, EarlyView.A new risk model for essential thrombocythemia that is based on complete blood cell count‐derived parameters and host‐related factors. ABSTRACT Survival prediction models in essential thrombocythemia (ET) include the International Prognostic Scoring System (IPSET) and the more recently introduced triple‐A (AAA) prognostic score.
Ayalew Tefferi +21 more
wiley +1 more source
Blood, 2019 Prior studies have reported high response rates with recombinant interferon-α (rIFN-α) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
A. Yacoub +33 more
semanticscholar +1 more source
From leeches to personalized medicine: evolving concepts in the management of polycythemia vera
Haematologica, 2017 Polycythemia vera is a clonal disorder of hematopoietic stem/progenitor cells. It manifests as an expansion of red cell mass. It is the most common chronic myeloproliferative neoplasm. In virtually all cases, it is characterized by a V617F point mutation
Alessandro M. Vannucchi
doaj +1 more source
Isolated cerebellar infarction in a case of JAK 2 mutation-negative polycythemia vera: A case report
Brain Circulation, 2022 Polycythemia vera is a myeloproliferative disorder caused by clonal expansion of erythroid precursors in the bone marrow commonly due to a mutation in the Janus kinase 2 (JAK2) gene located in the short arm of chromosome 9. Hyperviscosity of blood due to
Prasad Krishnan
doaj +1 more source
Studies on the iron metabolism of erythroblasts in various blood diseases [PDF]
, 1960 The serum iron contents and the number of sideroblasts from various patients and the radioactivity of erythroblasts from the same patients incubated with Fe55 have been observed.
Kimura, Ikuro +2 more
core +1 more source
Cleveland Clinic Journal of Medicine, 1989 The occurrence of polycythemia vera in a father, mother, and two sons is reported. Thirteen kindreds with familial polycythemia vera in 31 members are reviewed. Comprehensive records were available for all four patients as well as other family members, since all were diagnosed and treated at the author's institution over a period of nearly 50 years ...
Robin L. Miller +2 more
openaire +3 more sources
Blood Advances, 2019 In the last years, a growing amount of evidence has been produced regarding the role of leukocytosis as a risk factor for thrombosis in patients with myeloproliferative neoplasms, predominantly in polycythemia vera (PV) and essential thrombocythemia (ET).
A. Carobbio +5 more
semanticscholar +1 more source